Japanese biotech firm PeptiDream (TYO: 4587) has inked a deal with Merck & Co (NYSE: MRK), for the discovery and development of COVID-19 therapeutics.
The firms will work together to create novel peptide therapies targeting both the current SARS-CoV-2 virus outbreak, as well as potential future coronavirus outbreaks.
Shares in PeptiDream, a Kanagawa-based company, jumped over 7% following the announcement on Friday.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze